Lyra Therapeutics (LYRA) Misses Q1 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Lyra Therapeutics (LYRA) PT Lowered to $10 at BofA Securities
May 2, 2024 5:37 AM EDTBofA Securities analyst Jason Gerberry lowered the price target on Lyra Therapeutics (NASDAQ: LYRA) to $10.00 (from $11.00) while maintaining a Buy rating.
The analyst comments "This morning we caught up with Lyra management to discuss its key pipeline program, Phase 3 LYR-210 (steroid implant) for CRS... More
